05:09 PM EDT, 05/14/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) reported a Q1 net loss late Tuesday of $1.12 per diluted share, compared with a loss of $12.10 per share a year earlier.

A single analyst polled by Capital IQ expected a loss of $0.80.

No revenue was reported for the quarter ended March 31, as expected for the clinical-stage drugmaker.